Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study]

International Journal of Clinical Practice

Volumn 68, Issue 11, 2014, Pages 1364-1375

  Van Dongen, V C P C ^a   Vanelderen, P J L ^b   Koopmans Klein, G ^c   Van Megen, Y J B ^c   Van Zundert, J ^b   Huygen, F J P M ^d  

^a Sittard Geleen Heerlen   (Netherlands)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c Mundipharma Pharmaceuticals BV   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NALOXONE PLUS OXYCODONE; OPIATE; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYCODONE NALOXONE COMBINATION;

ADULT; AGED; ARTICLE; BELGIUM; BOWEL FUNCTION INDEX; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NETHERLANDS; NEUROLOGIC DISEASE; OPEN STUDY; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL; PRURITUS; QUALITY OF LIFE; SKIN DISEASE; SOMNOLENCE; TREATMENT DURATION; VOMITING; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; MIDDLE AGED; OPIOID-RELATED DISORDERS; PSYCHOLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC PAIN; CONSTIPATION; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; OPIOID-RELATED DISORDERS; OXYCODONE; PATIENT PREFERENCE; QUALITY OF LIFE;

EID: 84908631548     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12468     Document Type: Article

References (33)

1. Breivik H, Collett B, Ventafridda V,. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333.
2. Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011; 27: 449-62.
3. Mueller-Lissner S,. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther 2010a; 27: 1-10.
4. McNicol E,. Opioid side effects. Pain 2007; 15: 1-5.
5. Becker G, Galandi D, Blum HE,. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007; 34: 547-65.
6. Pappagallo M,. Incidence, prevalence and management of opioid bowel dysfunction. Am J Surg 2001; 182 (Suppl.): 11S-8S.
7. Panchal SJ, Müller-Schwefe P, Wurzelmann JI,. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007; 61: 1181-7.
8. Kurz A, Sessler DI,. Opioid-induced bowel dysfunction. Drugs 2003; 63: 649-71.
9. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R,. The prevalence, severity and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med 2009a; 10: 35-42.
10. Bell T, Annunziata K, Leslie JB,. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the national Health and wellness survey. J Opioid Manag 2009b; 5: 137-44.
11. Dunlop W, Uhl R, Khan I, Taylor A, Barton G,. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged releaswe oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012; 15: 1-12.
12. Kwong WJ, Diels J, Kavanagh S,. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother 2010; 44: 630-40.
13. Iyer S, Davis KL, Candrilli S,. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care 2010; 19: 44-51.
14. Hjalte F, Berggren A-C, Bergendahl H, Hjortsberg C,. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010; 40: 696-703.
15. Leppert W,. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther 2010; 27: 714-30.
16. Nadstawek J, Leyendecker P, Hopp M, et al. Patient assesment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 2008; 62: 1159-67.
17. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M,. A randomized, double-blind, active-controlled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012; 26: 50-60.
18. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9: 1144-54.
19. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24: 3503-12.
20. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009; 13: 56-64.
21. Loewenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients recieving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009; 10: 531-43.
22. Loewenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. Clin Pharmacol 2010; 10: 1-9.
23. Mueller-Lissner S,. Opioid-induced constipation-mechanisms, relevance and management. Eur Gastroenterol Hepatol Rev 2010b; 6: 1-6.
24. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P,. Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371-83.
25. Ueberall MA, Mueller-Lissner S, Buschmann-Kramm C, Bosse B,. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 2011; 39: 41-50.
26. Tessaro L, Bandieri E, Costa G, et al. Use of oxycodone controlled-release immediately after NSAIDs: a new approach to obtain good pain control. Eur Rev Med Pharmacol Sci 2010; 14: 113-21.
27. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010; 64: 1-12.
28. Schutter U, Grunert S, Meyer C, Schmidt T, Nolte T,. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010; 26: 1377-87.
29. Chang JY, Richard Locke G, Schleck CD, Zinsmeister AR, Talley NJ,. Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil 2007; 19: 905-11.
30. Fosnes GS, Lydersen S, Farup PG,. Constipation and diarrhoea-common adverse drug reactions? A cross sectional study in the general population. BMC Clin Pharmacol 2011; 11: 1-9.
31. Soer R, Reneman MF, Speijer BLGN, Coppes MH, Vroomen PCAJ,. Clinimetric properties of the EuroQol-5D in patients with chronic low back pain. Spine J 2012; 12: 1035-9.
32. Gatti A, Casali M, Lazzari M, et al. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation. Adv Ther 2013; 30: 41-59.
33. SPC OxyContin. http://www.cbg-meb.nl (accessed October 2013).